Literature DB >> 27761621

Radioiodine - the success story of Nuclear Medicine : 75th Anniversary of the first use of Iodine-131 in humans.

V Ralph McCready1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27761621     DOI： 10.1007/s00259-016-3548-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  23 in total

1.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

2.  Interventional nuclear medicine.

Authors:  V Ralph McCready; Sabina Dizdarevic; Mark Aplin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

3.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

4.  Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.

Authors:  N Gopalakrishna Iyer; Luc G T Morris; R Michael Tuttle; Ashok R Shaha; Ian Ganly
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

5.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.

Authors:  Douglas S Ross; Henry B Burch; David S Cooper; M Carol Greenlee; Peter Laurberg; Ana Luiza Maia; Scott A Rivkees; Mary Samuels; Julie Ann Sosa; Marius N Stan; Martin A Walter
Journal:  Thyroid       Date:  2016-10       Impact factor: 6.568

6.  Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.

Authors:  Liam Welsh; Ceri Powell; Brenda Pratt; Kevin Harrington; Chris Nutting; Clive Harmer; Kate Newbold
Journal:  J Clin Endocrinol Metab       Date:  2013-03-14       Impact factor: 5.958

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

8.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

Authors:  Glenn D Flux; Masud Haq; Sarah J Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive L Harmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

9.  Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials.

Authors:  Junqi Wang; Lan Qin
Journal:  Br J Radiol       Date:  2016-06-08       Impact factor: 3.039

Review 10.  Radioiodine therapy of thyroid autonomy.

Authors:  Christoph Reiners; Peter Schneider
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-18       Impact factor: 9.236
View more
  8 in total

1.  GUIDANCE TO THE MATERNAL, FETAL AND NEONATAL MANAGEMENT OF RESISTANCE GRAVE'S DISEASE IN PREGNANCY.

Authors:  D V Das; A Baro
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

2.  Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer.

Authors:  Justus Baumgarten; Christian Happel; Daniel Groener; Jennifer Staudt; Benjamin Bockisch; Amir Sabet; Frank Grünwald; Thomas Rink
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

Review 3.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

4.  Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves' disease.

Authors:  C Happel; W T Kranert; D Gröner; J Baumgarten; J Halstenberg; B Bockisch; A Sabet; F Grünwald
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

Review 5.  Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future.

Authors:  Laura Teodoriu; Letitia Leustean; Maria-Christina Ungureanu; Stefana Bilha; Irena Grierosu; Mioara Matei; Cristina Preda; Cipriana Stefanescu
Journal:  Diagnostics (Basel)       Date:  2022-04-10

6.  Cross-Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications.

Authors:  Veronika Rosecker; Christoph Denk; Melanie Maurer; Martin Wilkovitsch; Severin Mairinger; Thomas Wanek; Hannes Mikula
Journal:  Chembiochem       Date:  2019-05-08       Impact factor: 3.164

7.  Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach.

Authors:  Haitao Zhao; Yu Qin; Dunfang Liu; Xinyao Geng; Cheng Wang; Ding Ding; Xuan Ding; Qian Xia; Jianjun Liu; Ruowen Wang; Weihong Tan
Journal:  Molecules       Date:  2022-09-23       Impact factor: 4.927

8.  Validation of the plasmid study to relate DNA damaging effects of radionuclides to those from external beam radiotherapy.

Authors:  Elise Verger; Jordan Cheng; Vittorio de Santis; Madeleine Iafrate; Jessica A Jackson; Cinzia Imberti; Gilbert O Fruhwirth; Philip J Blower; Michelle T Ma; Daniel R Burnham; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2021-06-15       Impact factor: 2.408
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.